Figure 4.

((R)-2-({1-[(5-ethyl-1,3,4-thiadiazol-2-yl) carbamoyl]cyclopentyl}methyl) valeric acid) (UK-414,495) enhanced vasoactive intestinal peptide (VIP)-induced increases in vaginal blood flow (VBF) in the anaesthetized rabbit model of sexual arousal. Intravenous infusion of VIP (6, 20 and 60 µg·kg⁻¹) produced a significant enhancement in VBF when compared with basal flow (ΔVBF). Pretreatment with UK-414,495 (50 × IC₅₀) significantly enhanced VIP-induced increases in VBF (A and B). In addition to enhancing the amplitude of blood flow changes, UK-414,495 also significantly increased the area under the curve (AUC, C) and the duration of VIP-mediated increases in VBF (the duration is measured at 50% of peak response). UK-414,495 had no effects on basal VBF. All changes were monitored using laser Doppler technologies, and data are expressed as mean ± SEM (n= 3–4), *P < 0.05 Student's unpaired t-test, compared with increases observed during vehicle infusions.